Drugs / KW-2450
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01199367 | Dec 2010 → Dec 2012 | breast cancer | Kyowa Kirin, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT00921336 | Jun 2009 → Aug 2010 | cancer | Kyowa Kirin, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KW-2450 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01199367 ↗ |
| Action | Inhibit | “Insulin-like growth factor I receptor inhibitor” CHEMBL5315324 ↗1“Insulin receptor inhibitor” CHEMBL5315324 ↗ |
| Modality | Small molecule | — CHEMBL5315324 ↗ |
| Route | Oral | “Subjects at each dose level will receive KW-2450 orally, once daily for 28 days followed by a 1-week observation period.” NCT00921336 ↗ |
| Target | IGF1R | “Insulin-like growth factor I receptor inhibitor” CHEMBL5315324 ↗ |
| Target | INSR | “Insulin receptor inhibitor” CHEMBL5315324 ↗ |